BioDlink Recognized by Client for Enabling the World’s First Dual-Payload ADC to Enter Clinical Trials

2026-02-09 - 13:38

BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world’s first dual-payload antibody–drug conjugate (ADC) to enter clinical development. BioDlink enabled IND approval 1.5 months ahead of schedule through efficient process development, manufacturing, and analytical execution. SUZHOU, China, Feb. 9, 2026 /PRNewswire/ — BioDlink announced that it